6-甲基喹喔啉 | 6344-72-5

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-甲基喹喔啉
• 英文名称: 6-methylquinoxaline
• CAS: 6344-72-5
• 化学式: C₉H₈N₂
• mdl: MFCD00041001
• 分子量: 144.176
• InChiKey: OSRARURJYPOUOV-UHFFFAOYSA-N

物化性质

• 熔点：
  218.5°C
• 沸点：
  244-245°C
• 密度：
  1.1164
• 闪点：
  244-245°C
• LogP：
  1.872 (est)
• 保留指数：
  1960.2
• 稳定性/保质期：

  在常温常压下，它是一种稳定的无色液体。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S23,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H315,H319
• 储存条件：
  避光、存于阴凉干燥处并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
6-Methylquinoxaline
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P362: Take off contaminated clothing and wash before reuse
P321: Specific treatment (see on this label)
P332+P313: If skin irritation occurs: Get medical advice/attention
P337+P313: If eye irritation persists get medical advice/attention

---

Section 3. Composition/information on ingredients.
6-Methylquinoxaline
Ingredient name:
CAS number: 6344-72-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8N2
Molecular weight: 144.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

喹喔啉及其衍生物是重要的化工中间体，在医药、农药、饲料及染料等领域得到广泛应用。近年来，许多研究结果表明，6-甲基喹喔啉在治疗肥胖症和抗肿瘤等方面表现出一定的药理活性，具有较高的研究价值和应用前景，备受人们的关注。

功效作用

6-甲基喹喔啉可能在抑制或杀灭癌细胞方面带来重大突破，这促使人们进一步深入研究喹喔啉衍生物的合成及其抗肿瘤活性。

反应信息

• 作为反应物：
  描述：

  6-甲基喹喔啉 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 以60%的产率得到6-溴甲基喹喔啉
  参考文献：
  名称：

  三嗪腈对半胱氨酸蛋白酶人类组织蛋白酶L的抑制作用：酰胺S3口袋中的酰胺····杂芳烃π-堆积相互作用和硫属元素键合。

  摘要：

  我们报道了半胱氨酸蛋白酶人组织蛋白酶L（hCatL）的三嗪腈配体的广泛的“杂芳烃扫描”，以研究S3口袋入口处的肽酰胺键Gly67–Gly68上的π堆积。杂芳基·····肽键的堆叠由咪唑并吡啶配体与hCatL的共晶体结构支持。抑制常数（ķ我）受到杂环的多样性和与S3口袋局部环境的特定相互作用的强烈影响。结合亲和力变化三个数量级。与烃类似物相比，所有杂芳族配体均具有增强的结合力。从杂芳烃和肽键的局部偶极矩的方向预测的能量贡献无法得到证实。分子间的C-S⋅⋅⋅O= C相互作用（硫族元素键）与Asn66的主链C = O增强了苯并噻吩基（K i = 4 n m）和苯并噻唑基（K i = 17 n m）配体的结合。 S3口袋。还测试了配体的相关酶罗德沙星。

  DOI：

  10.1002/cmdc.201600563
• 作为产物：
  描述：

  1,2,3,4-四氢-6-甲基喹噁啉 在 potassium tert-butylate 作用下， 以 邻二甲苯 为溶剂， 反应 36.0h， 以93%的产率得到6-甲基喹喔啉
  参考文献：
  名称：

  叔丁醇钾促进的N-杂环无受体脱氢

  摘要：

  钾叔N-杂环的丁醇促进的acceptorless脱氢高效地实现用于N-杂芳烃和氢气的过渡金属-自由条件下产生。在存在KO t Bu碱的情况下，各种六元和五元N-杂环化合物可以有效地进行无受体脱氢，从而在140°C的邻二甲苯中提供相应的N-杂芳烃和H 2气体。本协议提供了一条通往芳香族含氮化合物和H 2气体的便捷途径。

  DOI：

  10.1002/adsc.201900499
• 作为试剂：
  描述：

  2,3-二氨基甲苯 、 草酸醛 、 sodium hydrogensulfite 、 potassium carbonate 在 3,4-二氨基甲苯 、 6-甲基喹喔啉 、 二氯甲烷 、 二氧化铂 、 乙醇 作用下， 以 水 为溶剂， 50.0~70.0 ℃ 、55.15 MPa 条件下， 反应 0.25h， 以to produce 1,2,3,4-tetrahydro-6-methylquinoxaline的产率得到1,2,3,4-四氢-6-甲基喹噁啉
  参考文献：
  名称：

  High temperature epoxy resins from hydrogenated quinoxalines

  摘要：

  一种多功能环氧树脂，具有良好的高温性能，可在120度以上的温度下长时间使用，其源自于公式（I）的前体：##STR1## 其中R.sup.3到R.sup.8包括氢，C.sub.1到C.sub.3烷基或卤代烷基，R.sup.9是氢，烷基或卤素，n的值为0，1或2。前体（I）可以自我偶联或与TGDDM类型的其他环氧化合物的前体交联。这种交联产生了一个复杂的混合物，其中不仅包含混合产物，还包括每个组分的自我偶联产物。无论混合物的精确化学组成如何，观察到的玻璃化转变温度比没有前体（I）形成的TGDDM树脂高。如果R.sup.9位置的取代基是烷基或卤素，则寡聚物形成被抑制，结果是一个较简单的混合物。

  公开号：

  US05710242A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
  申请人：——

  公开号：US20030083357A1

  公开（公告）日：2003-05-01

  The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

  本发明涉及Formula (I)的化合物，可能在治疗疾病，如代谢紊乱、血脂异常和/或高胆固醇血症方面有用：
• Heterocyclic derivatives for the treatment of diabetes and other diseases
  申请人：Maxia Pharmaceuticals, Inc.

  公开号：US06515003B1

  公开（公告）日：2003-02-04

  The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

  本发明涉及某些Formula (I)的取代杂环，这些取代杂环在治疗与脂质和碳水化合物代谢相关的疾病方面很有用，如2型糖尿病、脂肪细胞分化、不受控制的增殖，如淋巴瘤、霍奇金病、白血病、乳腺癌、前列腺癌或一般癌症；以及炎症，如骨关节炎、类风湿关节炎、克罗恩病或炎症性肠病。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。

表征谱图